Understanding Clinician Macrocognition to Inform the Design of a Congenital Heart Disease Clinical Decision Support System.

Front Cardiovasc Med

Department of Engineering and Applied Sciences, Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada.

Published: February 2022

AI Article Synopsis

  • Children with congenital heart disease (CHD) face unique challenges during emergency situations, as symptoms can resemble common childhood illnesses, potentially leading to misdiagnosis or delayed treatment by emergency department (ED) physicians.
  • CHD experts and ED physicians exhibit different cognitive processes in diagnosing and treating CHD patients, with experts quickly identifying cardiac issues while ED physicians tend to take longer to connect non-specific symptoms to CHD.
  • The study's findings highlight the need for a web-based decision support tool to assist ED physicians in better recognizing and managing cases of CHD.

Article Abstract

Background And Objectives: Children with congenital heart disease (CHD) are at risk of deterioration in the face of common childhood illnesses, and their resuscitation and acute treatment requires guidance of CHD experts. Many children with CHD, however, present to their local emergency departments (ED) with gastrointestinal and respiratory symptoms that closely mimic symptoms of CHD related heart failure. This can lead to incorrect or delayed diagnosis and treatment where CHD expertise is limited. An understanding of the differences in cognitive decision-making processes between CHD experts and ED physicians can inform how best to support ED physicians when treating CHD patients.

Methods: Cardiac intensivists (CHD experts) and pediatric emergency department physicians (ED physicians) in a major academic cardiac center were interviewed using the critical decision method. Interview transcripts were coded deductively based on Schubert and Klein's macrocognitive frameworks and inductively to allow for new or modified characterization of dimensions.

Results: In total, 6 CHD experts and 7 ED physicians were interviewed for this study. Although both CHD experts and ED physicians spent a lot of time sensemaking, their approaches to sensemaking differed. CHD experts reported readily recognizing the physiology of complex congenital heart disease and focused primarily on ruling out cardiac causes for the presenting illness. ED physicians reported a delay in attributing the signs and symptoms of the presenting illness to congenital heart disease, because these clinical findings were often non-specific, and thus explored different diagnoses. CHD experts moved quickly to treatment and more time anticipating potential problems and making specific contingency plans, while ED physicians spent more time gathering a range of data prior to arriving at a diagnosis. These findings were then applied to develop a prototype web-based decision support application for patients with CHD.

Conclusion: There are differences in the cognitive processes used by CHD experts and ED physicians when managing CHD patients. An understanding of differences in the cognitive processes used by CHD experts and ED physicians can inform the development of potential interventions, such as clinical decision support systems and training pathways, to support decision making pertaining to the acute treatment of pediatric CHD patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850471PMC
http://dx.doi.org/10.3389/fcvm.2022.767378DOI Listing

Publication Analysis

Top Keywords

chd experts
36
experts physicians
20
congenital heart
16
heart disease
16
chd
16
decision support
12
differences cognitive
12
processes chd
12
physicians
10
experts
9

Similar Publications

Congenital heart defects (CHDs) are the most common congenital defect, occurring in approximately 1 in 100 live births and being a leading cause of perinatal morbidity and mortality. Of note, approximately 25% of these defects are classified as critical, requiring immediate postnatal care by pediatric cardiology and neonatal cardiac surgery teams. Consequently, early and accurate diagnosis of CHD is key to proper prenatal and postnatal monitoring in a tertiary care setting.

View Article and Find Full Text PDF

The social determinants of health (SDOH) have been recognized as an important contributor to an individual's health status. A valid and reliable instrument is needed for researchers and clinicians to measure SDOH. However, there is considerable variability in the screening methodologies, as well as a lack of standardization in definitions and methods for capturing and reporting SDOH data for both electronic health record software vendors and national experts on SDOH.

View Article and Find Full Text PDF

Application of nanoultrasonography in early diagnosis of coronary heart disease.

Nanomedicine (Lond)

January 2025

Department of Ultrasound, Yantaishan Hospital, Binzhou Medical University, Yantai, Shandong, China.

Coronary heart disease (CHD) remains one of the leading causes of mortality and disability globally. In recent years, nanoultrasonography technology has demonstrated significant potential in both the diagnosis and treatment of CHD. This review summarizes the latest research advancements in nanoultrasonography within the field of coronary heart disease, focusing on its applications in early diagnosis, targeted drug delivery, imaging techniques, and treatment strategies.

View Article and Find Full Text PDF

Background: Existing evidence for associations of per- and polyfluoroalkyl substances (PFASs) with blood lipids, lipoproteins and apolipoproteins (apo), and coronary heart disease (CHD) risk is limited and inconsistent. This study aims to explore associations between plasma PFASs, blood lipoprotein subspecies defined by apolipoproteins, and CHD risk.

Methods: A case-control study of CHD was conducted in the Health Professionals Follow-Up Study (HPFS) and Nurses' Health Study (NHS).

View Article and Find Full Text PDF

Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).

Design: An explorative ancillary study of the French CrusoeNET cohort.

Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!